Creation of a Probabilistic Atlas of Normal Cerebral Uptake of 18F-FDG in PET/MRI.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-10

Study Completion Date

2023-03-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With 18F-FDG PET, we have few atlases of normality allowing the realization of objective quantitative analyses. An atlas of normality is a probabilistic atlas of normal FDG uptake from a representative set of brain PET images of healthy subjects. This type of atlas is essential for intra- and inter-individual comparisons.

Accurate quantitative analysis of brain 18F-FDG PET images acquired on a hybrid PET system has been shown to require an institutional normal database for statistical analyzes (Akdemir et al., JNM 2017 and Della Rosa et al Neuroinformatics, 2014).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Discard the Curative Causes of Late Onset Epilepsy: the Role of Brain 18F-FDG PET

NCT05831371

Late Onset Epilepsy Alzheimer Disease

UNKNOWN

Modelling in the Quantitative Analysis of Brain PET Scans in Patients With Alzheimer's Disease

NCT04718207

Patients With Alzheimer's Disease

COMPLETED

Risk of Developing Dementia and Associated Factors in Patients With Normal Brain FDG PET

NCT04804722

Neurodegenerative Diseases Cognitive Disorder

COMPLETED

18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study

NCT02556502

Amyloid PET Imaging

COMPLETED NA

Constitution of a Standardized Neural Imaging Database in Healthy Subjects

NCT00484523

Healthy

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, monocentric, non-randomized study, with no direct individual benefit since it involved healthy volunteers.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Healthy volunteers

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

18F-FDG injection

Health volunteers with 18-F-FDG injection

Group Type OTHER

brain PET-MRI with 18F-FDG

Intervention Type DIAGNOSTIC_TEST

Realisation of a brain PET-MRI with 18F-FDG in 39 healthy volunteers

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

brain PET-MRI with 18F-FDG

Realisation of a brain PET-MRI with 18F-FDG in 39 healthy volunteers

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged 20 to 50
* Absence of any history or cardiovascular, neurological or psychiatric deficit
* Signed the informed consent

Exclusion Criteria

* Contraindication to the realization of an MRI or PET and to the injection of 18F-FDG
* People using a pacemaker or insulin pump
* People wearing a metal prosthesis or an intracerebral clip
* People with intraocular metal splinters
* People with a pathology considered incompatible for the production of the atlas according to the investigator
* Pregnant women and breastfeeding women
* Subject in period of exclusion.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes